ClinicalTrials.gg
CompletedNCT06571175SAS-F-5Updated Oct 23, 2026

Quantification of Myocardial Fibrosis in Aortic Stenosis

An observational study in Aortic Valve Stenosis and Myocardial Fibrosis, sponsored by Norwegian University of Science and Technology. Completed at 1 site in Norway. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Norwegian University of Science and Technology · Observational

How we know

Updated Oct 23, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
79
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Aortic Valve Stenosis with a site in Norway — 2 open to participants now, 4 under way, none of them phase 3. Aortic Valve Stenosis · Norway.

Enrollment
11th of 15
79 · median 500
Started
2025
with 2 others
Observational
15 of 22
none open now
Registered
18th of 22
by date
Lead sponsor
3 of 22
Norwegian University of Science and Technology

Among the 22 studies in Aortic Valve Stenosis with a site in Norway, this one is the 11th largest by enrollment of the 15 observational ones that give a count, is one of 3 that started in 2025, is one of 15 observational ones, and was the 18th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

2 of the 22 studies in Aortic Valve Stenosis with a site in Norway are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Aortic Valve Stenosis with a site in Norway, or all of them as a file.
02

Study summary

This study is a long term follow-up of patients that were included as part of a previous study (NCT03422770), where patients with aortic stenosis and healthy controls went through echocardiography, cardiac MRI, long-term ECG-recording, blood tests and quality of life assessment. Echocardiography included high frame ultrasound for detection of natural mechanical waves, and the measured speed of these waves were used as a marker of the extent of myocardial fibrosis.

Up to five years have now passed since inclusion at baseline, and a proportion of the patients in the cohort have undergone aortic valve replacement at some point. In this study, the investigators will repeat the cardiac imaging (echocardiography and cardiac MRI), ECG and blood test, to assess long-term changes in myocardial fibrosis in aortic stenosis patients.

Read the detailed description

High frame rate ultrasound with quantification of myocardial mechanical wave velocities provides a new approach to evaluation of myocardial stiffness.

Principle: An elastic medium (the left ventricle) is incited by a force (naturally occuring mechanical wave generated by atrial contraction and/or closure of mitral and aortic valve), and the resulting oscillation wave propagates through the medium with a speed that depends only on the density and stiffness of the medium. If the density of the medium is known, measuring the propagation velocity of the wave is the same as measuring the stiffness of the medium.

There is a lack of longitudinal data in this research area. A follow-up study of the described cohort, will add valuable insight into high frame rate ultrasound as a potential tool to quantify myocardial fibrosis in heart failure patient, and to monitor any changes from baseline.

03

Conditions studied

  • Aortic Valve Stenosis
  • Myocardial Fibrosis

Keywords

  • High frame rate echocardiography
  • Heart failure
  • Aortic stenosis
  • Cardiac MRI
  • Prognosis
  • Quantification of severity
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients: Mild, moderate, or severe aortic valve stenosis. A subset of the patients will have undergone aortic valve replacement since inclusion.

Controls: Healthy with no valve disease, or other cardiac disease known to cause myocardial fibrosis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Part of the initial cohort that were included in the baseline study
  • Still able to undergo protocolled investigations
  • Patients: Mild, moderate or severe AS

Exclusion criteria

Exclusion Criteria:

  • Renal insufficiency
  • Previously myocardial infarction (, echocardiogram or hospital record)
  • Severe valvular heart disease (except patients)
  • Other cardiac disease known to cause myocardial fibrosis
  • Severe hypertension
  • Other medical conditions deterring protocolled investigation and follow-up
  • Other medical conditions affecting 5-years prognosis (cancer, pulmonary disease)
  • Severely reduced image-quality (echocardiography and MRI)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
79 participants (actual)
Patient registry
No

Groups and cohorts

  • Aortic stenosis

    Mild aortic stenosis:25 patients were included at baseline, and those that still avoid exclusion criteria, will be invited to undergo repeat echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG. Moderate aortic stenosis: 25 patients were included at baseline, and those that still avoid exclusion criteria, will be invited to undergo repeat echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG. Severe aortic stenosis: 50 patients were included at baseline, and those that still avoid exclusion criteria, will be invited to undergo repeat echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG.

    Diagnostic Test: High frame rate echocardiography · Diagnostic Test: MRI · Diagnostic Test: Blood test · Diagnostic Test: ECG and Holter-ECG · Diagnostic Test: 6 min walking test

  • Controls

    The controls from baseline inclusion will be invited to undergo repeat echocardiography, blood test and CMRI

    Diagnostic Test: High frame rate echocardiography · Diagnostic Test: MRI · Diagnostic Test: Blood test

Interventions

  • Diagnostic testHigh frame rate echocardiography

    Conventional transthoracic echocardiography will be performed, with added 3D-imaging and acquisitions with high frame rate. The data from these patients will be anonymized and transferred for post-hoc analysis in dedicated computer software (GE Vingmed, EchoPac 2.6) and in validated machine learning algorithms.

    Also known as: GE Vingmed ultrasound scanner E95, 2017

  • Diagnostic testMRI

    Cardiac MRI will be performed. In all patients without contraindications, a gadolinium-based contrast agent will be given.

    Also known as: Cardiac magnetic resonance imaging (CMRI)

  • Diagnostic testBlood test

    Conventional brachial venous blood samples will be drawn. Hematocrit value {in %} will be used to calculate CMR-derived exttracellular volume (ECV)

  • Diagnostic testECG and Holter-ECG

    ECG/Holter-ECG will be performed, and the findings will be related to the imaging findings.

  • Diagnostic test6 min walking test

    6 MWT will be performed, and the findings will be related to findings from CMRI/echocardiography.

06

What researchers measure

Primary outcomes

  1. Cardiovascular morbidity

    Admissions with heart failure

    Time frame: 5 year

  2. Cardiovascular mortality

    Death caused by cardiac disease

    Time frame: 5 year

Secondary outcomes

  1. All cause mortality

    Mortality in general

    Time frame: 5 years

  2. Time of first re-hospitalization

    Time of first re-hospitalization after inclusion

    Time frame: 5 years

  3. Cardiac systolic function

    Systolic function based on left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS). Unit of measure for LVEF and for GLS is % for both (a positive number for LVEF, and a negative number for GLS)

    Time frame: 5 years

  4. Cardiac diastolic function (1 of 5)

    Echocardiographic diastolic function based on i) left atrial volume index {ml/m\^2).

    Time frame: 5 years

  5. Cardiac diastolic function (2 of 5)

    Echocardiographic diastolic function based on ii) mitral annular velocities {cm/sec}

    Time frame: 5 years

  6. Cardiac diastolic function (3 of 5)

    Echocardiographic diastolic function based on iii) mitral inflow velocities {cm/sec}

    Time frame: 5 years

  7. Cardiac diastolic function (4 of 5)

    Echocardiographic diastolic function based on iv) ricuspid regurgitation velocity {cm/sec}

    Time frame: 5 years

  8. Cardiac diastolic function (5 of 5)

    Echocardiographic diastolic function based on v) E/è-ratio

    Time frame: 5 years

  9. Velocity of natural mechanical waves propagating through the myocardium

    Investigate for prognotisc value and if it can be a marker of diastolic dysfunction. Unit of velocity measurement is m/sec.

    Time frame: 5 years

07

Study locations

1 site
  • St. Olavs Hosptial
    Trondheim, Trøndelag 7030, Norway
08

References and documents

Publications

  • Salles S, Espeland T, Molares A, Aase SA, Hammer TA, Stoylen A, Aakhus S, Lovstakken L, Torp H. 3D Myocardial Mechanical Wave Measurements: Toward In Vivo 3D Myocardial Elasticity Mapping. JACC Cardiovasc Imaging. 2021 Aug;14(8):1495-1505. doi: 10.1016/j.jcmg.2020.05.037. Epub 2020 Aug 26. PubMed 32861651 ↗
  • M. Mohajery, S. Salles, T. Espeland, S. Fadnes and L. Lovstakken,
  • Espeland T, Wigen MS, Dalen H, Berg EAR, Hammer TA, Salles S, Lovstakken L, Amundsen BH, Aakhus S. Mechanical Wave Velocities in Left Ventricular Walls in Healthy Subjects and Patients With Aortic Stenosis. JACC Cardiovasc Imaging. 2024 Feb;17(2):111-124. doi: 10.1016/j.jcmg.2023.07.009. Epub 2023 Sep 6. PubMed 37676209 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Jun 2026, 16 months.

Of 206 non-industry observational studies under Aortic Valve Stenosis, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 120. This study's 16 months is below that.

Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Mar 2026 → Jun 2026 and completion Apr 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2024
First posted
Aug 26, 2024
StartActual
Jan 21, 2025
Primary completionActual
Jun 1, 2026was Mar 2026
CompletionActual
Aug 14, 2026was Apr 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Completed
changed Oct 23, 2026
Primary completion
Mar 1, 2026→Jun 1, 2026 (actual)
Oct 23, 2026
Study completion
Apr 15, 2026→Aug 14, 2026 (actual)
Oct 23, 2026
Enrollment
70 (estimated)→79 (actual)
Oct 23, 2026
Title
Quantification of Myocardial Fibrosis in AortisAortic Stenosis
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Enrolling by invitation→Completed
    Primary completion Mar 1, 2026→Jun 1, 2026 (now actual)
    Study completion Apr 15, 2026→Aug 14, 2026 (now actual)
    Enrollment 70 (estimated)→79 (actual)
    Title Quantification of Myocardial Fibrosis in AortisAortic Stenosis
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06571175
Responsible party
Sponsor
First posted
Aug 26, 2024
Start date
Jan 21, 2025
Primary completion
Jun 1, 2026
Completion
Aug 14, 2026
Last update
Oct 23, 2026

Study contacts

Brage H: Amundsen, MD, PhD
principal investigator · Norwegian University of Science and Technology (NTNU)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion